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A 67-year-old man presented to his primary care provider with a 3-day history of 
chest tightness, wheezing, coughing, and dyspnea. He reported a history of similar 
episodes that had been attributed to asthma, which was triggered by environmental 
allergens (mold, cats, grass, and ragweed). Although he had required hospitalization 
for asthma as a young man, his symptoms subsequently had been well controlled 
with inhaled triamcinolone, salmeterol, and loratadine, and he had had no major 
exacerbations for 20 years. He had rarely required his albuterol rescue inhaler. He 
reported no new allergen or environmental exposures, fevers, sputum production, 
hemoptysis, orthopnea, paroxysmal nocturnal dyspnea, edema, or weight loss. Pul-
monary examination was unremarkable, with a normal respiratory rate and no 
wheezes; a radiograph of the chest was normal. He was prescribed prednisone to be 
tapered gradually over a 2-week period for presumed exacerbation of asthma.
Given a history of asthma and current symptoms that subjectively mimic those of 
prior asthma exacerbations, treatment of a presumed asthma exacerbation is rea-
sonable. The absence of a clear trigger does not rule out asthma, particularly in a 
patient with multiple previously documented allergies. However, the long interval 
since his last exacerbation makes the diagnosis less certain.
His symptoms abated transiently but recurred shortly after the completion of the 
prednisone taper. He contacted his primary care provider, who prescribed another 
prednisone taper and provided prescriptions for refills of prednisone to treat any 
future exacerbations. Over the next several months, the patient reported that when-
ever his prednisone dose decreased below 20 mg per day, the symptoms recurred. He 
occasionally took additional prednisone doses in a rescue fashion, at doses of up to 
100 mg per day. Peak flows were approximately 550 liters per minute when he was 
asymptomatic and 400 to 450 liters per minute when he was symptomatic. A proton-
pump inhibitor and a course of oral antibiotic agents were prescribed but had no 
effect. Fatigue, arthralgias, and pain in the left lower quadrant developed, and the 
patient lost weight.
The persistence of symptoms despite multiple prednisone courses is worrisome, as 
is the new constellation of symptoms. Although the history suggests a glucocor-
ticoid-responsive process, I would not restrict the differential diagnosis according 
to glucocorticoid response. Indefinite use of glucocorticoids confers a risk of un-
toward consequences, including an increased risk of infection with prolonged use 
of prednisone at doses of 20 mg per day or higher, and is particularly troubling in 
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the absence of a clear diagnosis; I would taper the 
glucocorticoids. A careful review of the patient’s 
travel history (recent and remote) and environmen-
tal exposures is warranted, and further imaging 
should be considered.
Four months after the initial presentation, the pa-
tient continued to have pulmonary and systemic 
symptoms, for which glucocorticoid therapy was 
continued. His physical examination remained 
unremarkable. Laboratory evaluation showed a 
hematocrit of 34.4% (baseline [1 year previously], 
46.9%), a white-cell count of 10,700 per cubic mil-
limeter, and a platelet count of 569,000 per cubic 
millimeter. Computed tomography (CT) of the 
chest, abdomen, and pelvis revealed diverticulitis 
with a 6-cm abscess and opacification in the base 
of the left lung that was consistent with either a 
mass or an area of consolidation. The patient was 
advised to present to the emergency department 
for evaluation, and he did so 2 days after the CT. 
Repeat CT of the abdomen with the use of con-
trast material confirmed the presence of perfo-
rated diverticulitis with abscess and an incom-
pletely imaged necrotic mass in the left lower lobe 
that was greater than 3 cm in diameter, with 
ground-glass opacification in the posterior aspect 
of both lower lobes. These findings prompted his 
admission to the hospital.
The patient’s age places him at risk for diverticu-
litis, which is often polymicrobial; broad-spec-
trum antibiotic coverage is indicated. The only 
association between the diverticular abscess and 
his previous pulmonary symptoms may be the 
prednisone, which may have suppressed the clini-
cal manifestations of diverticulitis, thereby con-
tributing to the progression to perforation and 
abscess.
The patient’s medical history included hypercho-
lesterolemia, hypertension, colonic adenoma, be-
nign prostatic hypertrophy, and chronic leg edema 
that resulted from vein stripping. At 18 years of 
age, he had had prolonged pharyngitis that was 
attributed to streptococcal infection, for which he 
had declined treatment for religious reasons. Dur-
ing that period, deep-vein thrombosis had devel-
oped while he was on bed rest. Additional medica-
tions at the time of admission included rosuvastatin, 
irbesartan, hydrochlorothiazide, and ezetimibe. He 
had no known drug allergies but could not take 
amlodipine and nifedipine because of side effects.
The patient worked as an actuary and lived 
with his wife and their dog. He smoked a pipe and 
had a remote history of cigarette use (10 pack-
years, with no cigarette use for more than four 
decades). He reported that he did not drink alco-
hol or use illicit drugs. His family history was 
negative for cancer and gastrointestinal disease. 
On admission, levofloxacin and metronidazole 
were started, and percutaneous abdominal drain-
age was performed. However, he declined consul-
tation for consideration of lung biopsy, because he 
was reluctant to undergo further invasive proce-
dures. Bacterial cultures grew more than 20 colo-
nies of alpha-hemolytic streptococci (limited to the 
first quadrant) and mixed anaerobic flora. Fungal 
cultures were negative. The white-cell count was 
14,430 per cubic millimeter at admission and de-
clined to 11,560 per cubic millimeter at discharge 
2 days later. The hematocrit and platelet values 
were unchanged from those at admission. He 
was discharged while taking oral antibiotics and 
with the abdominal drain in place; visiting nurs-
ing care was provided. He was encouraged to 
pursue pulmonary evaluation in the outpatient 
setting.
Imaging in this patient has revealed a necrotic 
lung lesion for which he has declined evaluation. 
I would have strongly counseled the patient that 
biopsy would probably enable diagnosis and the 
initiation of appropriate treatment, whereas de-
laying diagnosis and treatment could result in 
further progression and complications. Ultimate-
ly, however, as long as a patient is competent to 
make decisions, he has the right to decline.
A few days after the patient was discharged, a 
soft, mildly tender, violaceous nodule appeared 
on the right side of the tip of his nose and rapidly 
enlarged to 1.5 cm in diameter over the next 3 
weeks. The patient then noted increasing edema 
in his lower legs bilaterally. Ultrasonography of 
the legs revealed deep-vein thromboses in the 
common femoral, superficial femoral, and popli-
teal veins bilaterally. He was hospitalized for fur-
ther treatment and an expedited evaluation, which 
he agreed to pursue.
His bilateral thromboses may reflect a previ-
ously undiagnosed thrombophilia, given his 
history of deep-vein thrombosis. However, his 
pulmonary abnormalities may have conferred a 
predisposition to deep-vein thrombosis; both 
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cancer and acute infection can increase the risk 
of venous thromboembolism.
Given the abnormal findings on chest imag-
ing and his prolonged symptoms, further pul-
monary evaluation is clearly indicated, but the 
new nasal lesion also warrants prompt atten-
tion. Given the extensive sun exposure of the 
nose, the rapid growth of the lesion, and tender-
ness on evaluation, a keratoacanthoma would be 
the most likely cancer. Other variants of squa-
mous-cell carcinoma are less likely to grow as 
rapidly in an immunocompetent host. Basal-cell 
carcinoma is unlikely, given the violaceous color 
and rapid growth of this lesion. Dissemination 
of internal cancers to the skin, although uncom-
mon, must be considered.
The nodule could also reflect an infectious 
process, which could involve bacterial, atypical 
mycobacterial, or fungal pathogens. The pulmo-
nary and cutaneous findings in this patient 
could be explained by a number of infectious 
pathogens, including nocardia, Cryptococcus neo-
formans, Sporothrix schenckii, or one of the geo-
graphically constrained fungi, such as Histoplas-
ma capsulatum and Blastomyces dermatitidis. 
Histoplasmosis rarely causes skin lesions in 
immunocompetent hosts; in this patient, the 
long-term glucocorticoid use may have been a 
predisposing factor. Rheumatologic processes 
that cause cutaneous and pulmonary abnormali-
ties, such as sarcoidosis or granulomatosis with 
polyangiitis, are less likely.
Further history revealed that the patient was born 
in the Midwest and lived in Iowa, Wisconsin, and 
Illinois before moving to Massachusetts as a teen-
ager. He had never traveled outside the United 
States. His most recent travel had been to Chica-
go, 2 months after symptom onset.
His travel history suggests that the geographi-
cally constrained fungi H. capsulatum and B. der-
matitidis are considerations. Both these fungi are 
found in the Midwest.
The patient consented to hospitalization. On ad-
mission, he appeared well-nourished and in no 
acute distress. The temperature was 36.5°C 
(97.7°F), the blood pressure 116/76 mm Hg, the 
pulse 90 beats per minute, the respiratory rate 16 
breaths per minute, and the oxygen saturation 
100% while the patient was breathing ambient 
air. The oropharynx was clear, without thrush or 
other lesions. The jugular venous pressure was 
not elevated. The lungs were clear to auscultation. 
Cardiovascular examination revealed a regular 
rate and rhythm without murmurs, rubs, or gal-
lops. The abdomen was soft and nontender, with 
normal bowel sounds and without hepatospleno-
megaly. There was no cervical, supraclavicular, 
axillary, or inguinal lymphadenopathy. The hands 
and feet were warm. There was 2+ pitting edema 
in the lower legs. Skin examination revealed Fitz-
patrick type II skin (burns easily, tans minimally) 
with a 1.5-cm violaceous nodule over his right 
nasal sidewall (Fig. 1). The nodule was fluctuant 
with a scaly surface and was tender to deep palpa-
tion, expressing some mucopurulent discharge 
with manipulation.
Although the nasal lesion could be a squamous-
cell carcinoma, such lesions are usually firm. In 
addition, the presence of mucopurulent dis-
charge suggests infection rather than cancer. At 
this time, an expedited laboratory workup 
should be conducted, including testing for se-
rum cryptococcal antigen, antinuclear antibody, 
Figure 1. Nodule, Measuring 1.5 cm in Diameter, on 
the Right Side of the Tip of the Nose.
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antineutrophil cytoplasmic antibody, and hu-
man immunodeficiency virus (HIV); in addition, 
a nasal biopsy should be performed and bron-
choscopy should be considered.
The white-cell count was 4800 per cubic millime-
ter (71% polymorphonuclear cells, 20% lympho-
cytes, 7% monocytes, and 2% eosinophils), the 
hematocrit 36% with a mean corpuscular volume 
of 96.2 fl, and the platelet count 363,000 per cubic 
millimeter. A comprehensive metabolic panel and 
coagulation studies were normal. The iron level 
was 57 μg per deciliter (10 μmol per liter; refer-
ence range, 37 to 158 μg per deciliter [7 to 28 μmol 
per liter]), the total iron-binding capacity 231 μg 
per deciliter (41 μmol per liter; reference range, 
250 to 450 μg per deciliter [45 to 81 μmol per li-
ter]), and the ferritin level 873 ng per milliliter 
(reference range, 10 to 170). Testing for HIV anti-
body was negative. Gram’s staining of discharge 
from the nasal lesion showed 1 to 5 polymorpho-
nuclear cells per low-power field and no organ-
isms. Culture grew coagulase-negative staphylo-
coccus. A hypercoagulation workup (including 
assessment of activated protein C resistance, mea-
surement of levels of protein C, protein S, homo-
cysteine, antithrombin III, and lupus anticoagu-
lant, and testing for the prothrombin gene 
mutation) was negative.
The anemia evaluation suggests a chronic in-
flammatory process. The results of the nasal-
lesion culture do not rule out other organisms. 
In fact, most of the previously mentioned fungal 
organisms and nocardia require special media 
or additional time to grow. A wet mount or a 
preparation with potassium hydroxide could 
identify fungal organisms. On a biopsy speci-
men, methenamine silver stain would be the 
preferred stain to identify fungi. If yeast forms 
Figure 2. CT Images of the Chest and Head.
A positron-emission tomographic (PET)–computed tomographic (CT) scan of the chest showed a lingular mass 
measuring 4.5 cm by 2.7 cm (Panel A, arrow), with moderate 18F-fluorodeoxyglucose (FDG) uptake (Panel B, arrow). 
A CT image from a PET–CT scan of the head showed a right nasal lesion (Panel C, arrow), with intense FDG uptake 
in the lesion (Panel D, arrow).
A B
DC
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are found, the mucicarmine stain will identify 
the capsular material of C. neoformans. The nega-
tive result on Gram’s staining argues against 
nocardia, which is a thin, branching, gram-
positive bacillus. When a disseminated fungal 
infection is suspected, the most useful noninva-
sive diagnostic tests are serum testing for cryp-
tococcal antigen and urine testing for histoplas-
mosis antigen.
A pulmonary CT angiogram showed a segmental 
pulmonary embolism in the right lower lobe and 
a mass in the left lingula measuring 4.5 cm by 
2.7 cm, without adenopathy. Enoxaparin was 
started. A positron-emission tomographic (PET) 
scan showed moderate 18F-fluorodeoxyglucose 
(FDG) avidity in the lung mass and intense FDG 
uptake in the right nasal lesion (Fig. 2).
The PET scan is expensive and is of limited use-
fulness here. Moderate FDG avidity can be seen in 
both malignant and infectious processes. I suspect 
a disseminated infection, which is most likely to 
be fungal, given the patient’s previous residence 
in an area in which histoplasmosis and blasto-
mycosis are endemic, the lack of lymphadenopa-
thy, and the rapidly enlarging nasal nodule. A 
biopsy of the nasal lesion may provide a tissue-
based diagnosis.
The patient consented to excision of the nasal 
lesion. Pathological findings showed a well-dif-
ferentiated keratoacanthoma-like squamous-cell 
carcinoma.
As noted previously, fungal processes can be 
missed on initial staining. I would review the 
nasal-biopsy results, ensuring that proper stains 
(in particular, methenamine silver and acid-fast 
stains) were used. If these tests were negative or 
could not be performed, a lung biopsy would be 
indicated.
A fine-needle aspiration of the lung revealed nec-
rotizing granulomatous inflammation. Gomori 
methenamine silver staining revealed fungal or-
ganisms consistent with blastomycosis (Fig. 3). 
Mucicarmine, acid-fast bacilli, Gram’s, and Fon-
tana–Masson stains were negative. On reexami-
nation of the nasal-biopsy specimen, periodic 
acid–Schiff staining confirmed the presence of 
blastomycosis with associated massive pseudo-
epitheliomatous hyperplasia that mimicked squa-
mous-cell carcinoma (Fig. 4). Urine testing for 
blastomyces antigen was positive at 4.3 units on 
enzyme immunoassay. The patient began receiv-
ing a 6-month course of itraconazole. His symp-
toms almost completely resolved within 1 month, 
and clinically significant regression of the pulmo-
nary parenchymal abnormalities was observed 
after 3 months. The blastomyces antigen level on 
urine testing slowly declined and was undetect-
able at the end of treatment. One year after his 
diagnosis, he remained symptom-free.
Figure 3. Fine-Needle Aspirate of the Lung.
A fine-needle aspirate of the lung stained with Gomori 
methenamine silver showed broad-based budding yeast 
(arrows) with features characteristic of Blastomyces 
dermatitidis.
Figure 4. Nasal-Biopsy Specimen.
A periodic acid–Schiff stained specimen from the nasal 
biopsy showed a B. dermatitidis yeast cell (arrow).
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Commen ta r y
Diagnosis of blastomycosis is often delayed be-
cause of the low clinical suspicion at the patient’s 
presentation and the range of associated clinical 
symptoms. In this patient, the respiratory symp-
toms, pulmonary imaging, and travel history 
could have prompted earlier diagnosis, but it 
was not until the nasal lesion appeared that the 
travel history was obtained.
Blastomycosis is caused by the thermally di-
morphic fungus B. dermatitidis. In North Ameri-
ca, B. dermatitidis is endemic in regions bordering 
the Great Lakes and the Saint Lawrence Seaway, 
as well as in the Mississippi and Ohio River val-
leys, the Canadian province of Manitoba, and 
the southeastern United States.1 B. dermatitidis 
causes disease when conidia are inhaled and 
converted to budding yeast at body temperature.2
Because exposure occurs primarily by means 
of inhalation, pulmonary involvement is the 
most common disease manifestation. Pulmo-
nary blastomycosis can be asymptomatic, acute, 
or chronic and can mimic cancer or infection 
with pyogenic bacteria, Mycobacterium tuberculosis, 
or fungi.2 Symptoms range from a mild influen-
za-like illness to cough with sputum production 
and dyspnea; in rare instances, infection can 
lead to the acute respiratory distress syndrome, 
most commonly in patients who have a history 
of diabetes and those who have had prior anti-
microbial therapy.2
Radiographic manifestations of pulmonary 
blastomycosis include focal masses, nodules, 
interstitial disease, air-space consolidation, and 
cavitary lesions.3 Patients with acute blastomyco-
sis tend to have air-space consolidation on imag-
ing, whereas those with chronic infection may 
present with mass lesions. Pleural effusions and 
lymphadenopathy are rare manifestations.3
Hematogenous dissemination can lead to 
extrapulmonary blastomycosis. The skin is the 
most common extrapulmonary site; cutaneous 
lesions occur in 80% of patients with pulmonary 
blastomycosis4 and, in contrast to lesions associ-
ated with histoplasmosis, commonly occur in 
immunocompetent as well as immunosuppressed 
hosts. Although primary cutaneous blastomyco-
sis is rare, it can occur by means of direct in-
oculation with B. dermatitidis. Both primary and 
secondary cutaneous blastomycosis can manifest 
as papulopustules, ulcers, nodules, or verrucous 
lesions that can be mistaken for squamous-cell 
carcinoma.1,5 Histopathologically, these lesions 
often show pseudoepitheliomatous hyperplasia 
with intraepidermal microabscesses and occasion-
al round yeast forms with broad-based budding.5 
Other sites of dissemination include the genito-
urinary tract, bone, and central nervous system. 
The risk of dissemination is increased among 
pregnant women and immunosuppressed per-
sons, including recipients of solid-organ trans-
plants,1,6 patients with advanced HIV disease,1,6 
and patients with prolonged glucocorticoid use.6
Methenamine silver or periodic acid–Schiff 
staining and direct visualization of B. dermatitidis 
in tissue specimens is the usual diagnostic 
method, especially in extrapulmonary disease.7 
B. dermatitidis can also be cultured from sputum 
and bronchial washings. Urine testing for B. 
dermatitidis antigen is an immunoassay with a 
sensitivity of 93% and specificity of 79% for 
blastomycosis.8 However, there is cross-reactivity 
with several other fungi.7,9
Treatment of moderate-to-severe pulmonary 
or disseminated blastomycosis consists of am-
photericin B for 1 to 2 weeks until symptoms 
abate, followed by itraconazole therapy for 6 to 
12 months. For mild-to-moderate disease, in-
cluding disseminated disease that is limited to 
the skin, monotherapy with itraconazole for 6 to 
12 months is recommended. Serum levels of 
itraconazole should be assessed after 2 weeks to 
ensure adequate levels.7
This case highlights the hazards of anchoring 
on an initial diagnosis despite the lack of a re-
sponse to therapy, the importance of reviewing 
primary data, including pathological specimens, 
and the importance of exposure history. Al-
though the patient’s reluctance to undergo inva-
sive evaluation complicated the diagnostic pro-
cess in this case, the history of residence in an 
area where blastomycosis is endemic was key to 
focusing the differential diagnosis. Although the 
evaluation ultimately led to the correct diagnosis 
and effective treatment, earlier diagnosis with 
less-invasive testing would have been possible.
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